{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:38:56Z","timestamp":1793709536289,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.06.016","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:41:42Z","timestamp":1782517302000},"page":"1909-1920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-8773","authenticated-orcid":false,"given":"Yong","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna Sand","family":"Dejmek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-708X","authenticated-orcid":false,"given":"Jorge","family":"Mena-Madrazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6294-6172","authenticated-orcid":false,"given":"Karen X.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6306-9046","authenticated-orcid":false,"given":"Mengli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuhua","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0820-8136","authenticated-orcid":false,"given":"Lingyan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.06.016_bib1","doi-asserted-by":"crossref","first-page":"100371","DOI":"10.1016\/j.ajpc.2022.100371","article-title":"There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness","volume":"12","author":"Makover","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.26599\/1671-5411.2024.04.001","article-title":"Writing Committee of the Report on Cardiovascular H, Diseases in C. Epidemiology and current management of cardiovascular disease in China","volume":"21","author":"Hu","year":"2024","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib3","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jacc.2025.08.060","article-title":"The burden of cardiovascular disease in China: incidence estimates from national surveillance (2023)","volume":"87","author":"Zheng","year":"2026","journal-title":"JACC"},{"key":"10.1016\/j.jacl.2026.06.016_bib4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jch.14642","article-title":"Association between pulse wave velocity and the 10-year risk of atherosclerotic cardiovascular disease in the Chinese population: a community-based study","volume":"25","author":"Yi","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jacl.2026.06.016_bib5","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.06.016_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.06.016_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2015.11.010","article-title":"A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality","volume":"10","author":"Wadhera","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.06.016_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","article-title":"The LDL cumulative exposure hypothesis: evidence and practical applications","volume":"21","author":"Ference","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5334\/gh.1154","article-title":"World Heart Federation Cholesterol Roadmap 2022","volume":"17","author":"Ray","year":"2022","journal-title":"Glob Heart"},{"key":"10.1016\/j.jacl.2026.06.016_bib10","first-page":"1","article-title":"2016 Chinese guidelines for the management of dyslipidemia in adults","volume":"15","author":"Joint committee for guideline revesion.","year":"2018","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib11","doi-asserted-by":"crossref","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","article-title":"2023 Chinese guideline for lipid management","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacl.2026.06.016_bib12","doi-asserted-by":"crossref","first-page":"105499","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacl.2026.06.016_bib13","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib14","doi-asserted-by":"crossref","first-page":"988576","DOI":"10.3389\/fcvm.2022.988576","article-title":"Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe","volume":"9","author":"Cheng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2026.06.016_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/1074248419899298","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol (LDL-C) goal achievement in high-cardiovascular-risk patients in Fuzhou, China","volume":"25","author":"Wang","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jacl.2026.06.016_bib16","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/CM9.0000000000002399","article-title":"Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study","volume":"136","author":"Chai","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jacl.2026.06.016_bib17","doi-asserted-by":"crossref","first-page":"101658","DOI":"10.1016\/j.beem.2022.101658","article-title":"Approach to patients with elevated low-density lipoprotein cholesterol levels","volume":"37","author":"Feingold","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2026.06.016_bib18","doi-asserted-by":"crossref","first-page":"1260921","DOI":"10.3389\/fphar.2023.1260921","article-title":"Inclisiran: a new generation of lipid-lowering siRNA therapeutic","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacl.2026.06.016_bib19","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.06.016_bib20","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib21","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacl.2026.06.016_bib22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2025.04.049","article-title":"Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD: the VICTORION-Mono randomized clinical trial","volume":"86","author":"Taub","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-016-0604-3","article-title":"Statins and their effect on PCSK9-impact and clinical relevance","volume":"18","author":"Taylor","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2026.06.016_bib24","doi-asserted-by":"crossref","first-page":"1612095","DOI":"10.3389\/fcvm.2025.1612095","article-title":"Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"12","author":"Cao","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2026.06.016_bib25","unstructured":"NCT05888103. Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol (V-Mono China). Available at ClinicalTrials.gov\/study\/NCT05888103."},{"key":"10.1016\/j.jacl.2026.06.016_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.phrs.2017.12.020","article-title":"Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review","volume":"130","author":"Bagherniya","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacl.2026.06.016_bib27","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/cpt.3213","article-title":"Chinese expert consensus on the clinical diagnosis and management of statin intolerance","volume":"115","author":"Li","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2026.06.016_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijcard.2015.01.024","article-title":"Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China","volume":"182","author":"Wei","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib29","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib30","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1253\/circrep.CR-25-0109","article-title":"Efficacy and safety of evolocumab in improving low-density lipoprotein cholesterol (LDL-C) levels in a Japanese population- systematic review and meta-analysis","volume":"7","author":"Sheng","year":"2025","journal-title":"Circ Rep"},{"key":"10.1016\/j.jacl.2026.06.016_bib31","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.06.016_bib32","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.06.016_bib33","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11886-022-01782-6","article-title":"PCSK9 inhibitor wars: how does inclisiran fit in with current monoclonal antibody inhibitor therapy? Considerations for patient selection","volume":"24","author":"Arnold","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacl.2026.06.016_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2026.06.016_bib35","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.06.016_bib36","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.06.016_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jacasi.2023.09.006","article-title":"Efficacy and safety of inclisiran in Asian patients. Results from ORION-18","volume":"4","author":"Huo","year":"2023","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacl.2026.06.016_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.06.016_bib39","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.06.016_bib40","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/CIRCULATIONAHA.124.073233","article-title":"Efficacy and safety of inclisiran in adolescents with genetically confirmed homozygous familial hypercholesterolemia: results from the double-blind, placebo-controlled part of the ORION-13 randomized trial","volume":"151","author":"Wiegman","year":"2025","journal-title":"Circulation"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:20:21Z","timestamp":1793708421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1933287426004083"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.06.016","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}